Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) Patients

NCT04490993 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

359

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-muscle Invasive Bladder Cancer

Interventions

DRUG: APL-1202 in combination with Epirubicin
DRUG: Placebo in combination with Epirubicin

Sponsor

Jiangsu Yahong Meditech Co., Ltd aka Asieris